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ABSTRACT: Technological advances in protein biochemistry
now enable researchers to modify the structure of peptides to
enable them to possess self-assembling properties, forming
hydrogels at low concentrations. Peptides can be altered
further to provide multifunctional characteristics, for example,
to demonstrate antimicrobial properties. The aim of this article
is to investigate the in vivo toxicity and antimicrobial
properties of a low molecular weight (naphthalene-2-ly)-
acetyl-diphenylalanine-dilysine-OH (NapFFKK-OH) peptide
hydrogel using an innovative waxworm (Galleria mellonella)
model, as an alternative to mammalian/vertebrate testing.
NapFFKK-OH hydrogels did not demonstrate any observable
in vivo toxicity or death in G. mellonella larvae over 5 days at
concentrations studied (≤2% w/v). A dose-dependent log10 reduction in viable (CFU/mL) Gram-positive (Staphylococcus
aureus, Staphylococcus epidermidis) and Gram-negative (Escherichia coli, Pseudomonas aeruginosa) bacteria implicated in
nosocomial infections was observed over 72 h. NapFFKK-OH was especially effective against in vivo infection models of S.
aureus with a significant 4.4 log10 CFU/mL reduction in viable bacteria at 2% w/v after 72 h. Our results show G. mellonella to
be a useful model for preliminary determination of in vivo toxicity and antimicrobial efficacy profiles of novel nanomaterials,
including peptide-based hydrogels. This contributes to the 3R principles of animal testing, reduction, refinement, and
replacement. The results also show NapFFKK-OH to be a promising alternative to standardly employed antimicrobials with the
potential to be utilized as a novel therapeutic in the treatment and prevention of hospital infections.
■ INTRODUCTION
The rise of healthcare-associated infections and their increasing
resistance to current therapeutic strategies are major concerns of
the modern society. This is problematic at global and cross-
sectoral levels, i.e., affecting humans, agriculture, and the
environment. It is acknowledged that the challenge faced is
best resolved by a multidisciplinary approach as highlighted by
the One Health approach to antimicrobial resistance, which
connects the human health and resistance concerns with that of
animals.1 It is predicted that if the current threat of antimicrobial
resistance is not resolved and innovative solutions are not
provided, 10 million lives will be at risk by 2050.2 A number of
therapeutic alternatives to standard antimicrobials are being
explored, some of which hold promise in the treatment and
prevention of hospital infections, including the use of
antimicrobial peptides.
Unlike most conventional antibiotics, antimicrobial peptides
target multiple sites (e.g., cell membrane and intracellular
processes) on bacterial cells rather than individual metabolic
processes; hence, the likelihood of resistance developing is
reduced.3 Research has also focused on the use of antimicrobial
peptides against biofilm phenotypes that demonstrate increased
tolerance to antimicrobial strategies and provide optimal
conditions for resistance to spread.4 Antimicrobial peptides
are able to interact with polysaccharide components of the
biofilm architecture, resulting in breakdown of their polymeric
matrix.5 Their promising activity has allowed peptides to
becomemarketed antimicrobials (e.g., daptomycin) with several
in the advanced stages of clinical trials for mainly topical
applications.6 However, concerns remain relating to the cost of
large-scale manufacturing, their potential for systemic delivery
due to reports of toxicity, and limited stability of L-enantiomeric
natural variants. To overcome these issues, many groups
including our own are focusing on ultrashort peptides. These
comprise up to seven amino acids and are thus increasingly
attractive peptide therapeutics due to reduction in associated
cost, ease of synthesis, and simple modifications allowing
improved resistance to proteolysis (e.g., use of D-enantiomers).7
Amino acids can also be rationally selected in line with a
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minimum pharmacophore required to permit antimicrobial
activity.8
Ultrashort peptides also have the ability to self-assemble to
higher architectures, for example, hydrogels, in response to
external, physiological stimuli (e.g., pH and specific enzymes).
This provides the peptide with a range of desirable, multifunc-
tional properties for biomedical use. Their potential applications
include as localized, topical treatments for infected wounds
owing to their antimicrobial activity and as controlled-release
drug delivery systems. The chemical, physical, and structural
properties that govern peptide self-assembly are closely
associated with factors that determine the antimicrobial potency
and spectrum of activity of synthetic antimicrobial peptides.9
Previous work by our group created ultrashort self-assembling
peptide hydrogels capable of killing biofilm forms of infection.10
(Naphthalene-2-ly)-acetyl-diphenylalanine-dilysine-OH
(NapFFKK-OH) was particularly promising, demonstrating
broad-spectrum activity against a range of biofilms implicated in
hospital-acquired infections. Although in vitro investigations
provide a useful indication of preliminary activity, in vivo studies
must be performed to facilitate translation of novel medical
products to a clinical setting. This provides several challenges
relating to ethics and cost.
Standard animal models include mainly vertebrae species,
including rabbits, mice, guinea pigs, andmonkeys.11,12 Concerns
exist relating to the use of such animals as a representation of
human health and disease; however, there are limited viable
alternatives.13 There has recently been increased emphasis on
the “Three Rs” (3Rs) concept and the necessity for novel or
alternative methods to in vivo testing.14 In vivo testing should be
used in cases where it will provide beneficial advances to human
or animal health or the environment. The 3Rs aim to reduce the
adverse effects caused to animals, improve animal welfare, and
enhance the quality of science in which animals are used so that:
the minimum possible number of animals is used (reduction);
they experience negligible pain or pain is avoided entirely
(refinement); and, if possible, nonanimal models are used for
experimentation (replacement). Refinement takes precedence
over reduction and replacement in that a method that uses a
greater number of animals but with milder harm is judged
preferable to one that uses fewer animals but causes greater
suffering to each individual animal.15
Alternative lower model organisms to traditional vertebrae
models, such as the invertebrate Galleria mellonella (greater wax
moth larvae), can serve as effective preliminary in vivo models
and a possible alternative to species protected by Schedule 3 of
the Animals (Scientific Procedures) Act 1986. Typically, there
are fewer ethical concerns regarding their use within in vivo
testing. G. mellonella serves as a useful tool of pathogenicity and
infection for human bacterial and fungal species.16 It is widely
available, economically advantageous, small in size (15−25
mm), and possesses a short life cycle, meaning that it can be
handled easily and injected with smaller quantities (20 μL) of
test compounds. G. mellonella serves as an ideal model for
clinical infections as it can be maintained at physiological
temperatures (37 °C) for up to 5 days.17−19
A number of studies have been conducted using Galleria as
infection models including those outlined in the review by Tsai
and colleagues.20 G. mellonella’s innate response to infections is
structurally and functionally similar to that of mammals.
Humoral responses trigger release of reactive oxygen species
and antimicrobial peptides into the hemolymph (blood system).
Hemolymph clotting, equivalent to mammalian blood clotting,
occurs followed by melanization triggered by an upstream
proteolytic cascade involving serine proteases. The cellular
response results in encapsulation of the infecting pathogen and
phagocytosis.17,21,22 Previously conducted antimicrobial inves-
tigations have demonstrated Galleria and mammalian immune
systems to share some important similarities, highlighting the
promise of Galleria as an alternative model to determine
antimicrobial efficacy and immune response.23−25 Validation of
antimicrobial efficacy and determination of pharmacokinetic
and pharmacodynamic properties have also been investigated
using G. mellonella models.26,27
In this study, we performed preliminary in vivo toxicity studies
via inoculation of G. mellonella larvae with self-assembling
antimicrobial peptide hydrogels (NapFFKK-OH: 0.5−2% w/v)
and found that the peptide was less toxic than in vitro studies had
indicated. We determined a suitable inoculum concentration
threshold to represent in vivo bacterial infection and evaluated
the ability of NapFFKK-OH to reduce infection inG. mellonella.
A reduction in both Gram-positive and Gram-negative
infections was observed over 24 and 72 h treatment windows.
Figure 1.G. mellonella demonstrated full survival after injection with varying concentrations (0.5−2% w/v) of the NapFFKK-OH hydrogel: (A) 30 °C
and (B) 37 °C, 120 h after administration.
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■ RESULTS
NapFFKK-OH In Vivo Toxicity. The NapFFKK-OH
peptide hydrogel proved to be biocompatible at concentrations
studied (0.5−2% w/v). No death and minimal melanization
were observed for all treatment groups after 120 h (Figure 1).
Verifying Maximum Nonlethal Dose of Bacteria. G.
mellonella larvae were treated with a range of inoculating doses
(1 × 108−1 × 102 CFU/mL) and observed for death alongside
phosphate-buffered saline (PBS) controls. The maximum
nonlethal dose was determined and used as the inoculating
dose for infection model studies, as displayed in Tables S1−S4,
highlighted in yellow. Of the four pathogens investigated,
Staphylococcus epidermidis proved to be the least lethal with
100% survival observed at concentrations as high as 1 × 107
CFU/mL bacteria. Staphylococcus aureus and Escherichia coli
displayed moderate killing activity (1 × 105 CFU/mL).
Pseudomonas aeruginosa proved to be the most lethal, with
limited survival above concentrations of 1 × 102 CFU/mL.
Infection Models. Infection models were performed over
the shorter time frame of 24 and 72 h to avoid cocooning of
waxworms that began to be observed over longer incubation
times at 37 °C. A range of reduction in bacterial numbers was
observed for each pathogen between 2.5 and 4.5 log10 CFU/mL
(Figures 2 and 3). For 24 and 72 h time points, the greatest
reduction was seen for S. aureus 2% w/v NapFFKK-OH treated
larvae with significant reduction observed at concentrations of
≥1% w/v NapFFKK-OH after 72 h.
■ DISCUSSION
NapFFKK-OH hydrogel toxicity studies using in vivo models of
G. mellonella expand on previously conducted in vitro studies by
our group whereby a monolayer of murine fibroblast NCTC 929
cells was exposed to varying concentrations of solubilized and
hydrogel forms of NapFFKK-OH. NapFFKK-OH was nontoxic
in the solubilized micromolar range (≤500 μM: >80% cell
metabolic activity),28 according to the International Standard
classification for biomaterial toxicity,29 but less than 60%NCTC
929 cell metabolic activity was observed at concentrations of
≥1.5% w/v in the hydrogel form.10 By comparison, the in vivo
studies presented (Figure 1) indicate that in more complex cell
environments, for example, at an organism level, toxicity is less
pronounced. There was no evidence of Galleria death (100%
survival) following inoculation with test concentrations of
NapFFKK-OH (0.5−2% w/v). Placebo inoculum (PBS
controls) served as evidence that no death or injury resulted
as part of the handling or injection process.30 Inoculation of
Galleria larvae via the proleg, directly into the hemolymph,
reduced the likelihood of precipitating release of stress factors,
which results in melanization. There was, however, evidence of
melanization in most treatment groups by 120 h, which could
also be attributable to incubation time and possible cocooning
rather than stress factor release.17
Use of Galleria as an infection model was required to be
validated to produce consistent, reproducible, and statistically
relevant results.31 The maximum nonlethal dose defined as one
sufficient to kill a proportion of larvae during the validation time
(120 h) was decided as the maximum concentration of bacteria
at which there was at least 80% or greater survival.18 A 10-fold
serial dilution method of bacterial inoculum, similar to that of
Olsen and colleagues, was adopted.25 Survival data was linked to
inoculum concentration (Tables S1−S4), whereas PBS controls
ensured that viability was independent of injection and handling.
Larvae death was confirmed by a change of color from golden to
dark brown/black and lack of movement when manipulated
with a pipette tip.32 S. epidermidis proved the least fatal with
survival even at concentrations as high as 1 × 107 CFU/mL
(Table S2). Higher concentrations of S. aureus (1× 108−1× 106
CFU/mL) resulted in significant melanization (Table S1). To
minimize the influence of innate larval self-defense mechanisms
on survival and bacterial numbers, an inoculum of 1× 105 CFU/
mL was chosen for further NapFFKK-OH investigations. A
similar assumption was adopted for E. coli samples (Table S3). P.
aeruginosa proved particularly lethal as observed by other
researchers. Inoculating doses employed previously by other
papers include 1.4× 103 CFU/mL,33 and those as low as 1× 102
CFU/mL have proven capable of inducing mortality.34
However, within our investigation, a low dose of 1 × 102
CFU/mL provided sufficient viability within the 80% maximum
nonlethal dose threshold to be used as the inoculating
concentration for infection models (Table S4).
Infection models were performed using inoculating concen-
trations determined from the validation assays (highlighted in
Figure 2. Bacterial viable counts (log10 CFU/mL) after 24 h treatment
of infected G. mellonella larvae (n = 5) with NapFFKK-OH hydrogels
(0.5−2% w/v). Key: dark gray, S. epidermidis ATCC 35984; white, S.
aureus ATCC 6538; light gray, E. coli NCTC 11303; black and white
checked, P. aeruginosa PAO1; and NS, no significant difference (p ≥
0.05) between negative untreated control and peptide treatment.
Figure 3. Bacterial viable counts (log10 CFU/mL) after 72 h treatment
of infected G. mellonella larvae (n = 5) with NapFFKK-OH hydrogels
(0.5−2% w/v). Key: dark gray, S. epidermidis ATCC 35984; white, S.
aureus ATCC 6538; light gray, E. coli NCTC 11303; black and white
checked, P. aeruginosa PAO1; NS, no significant difference (p ≥ 0.05);
*p < 0.05 significant difference; **p < 0.01 significant difference; ***p
< 0.001 significant difference between negative untreated control and
peptide treatment.
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yellow in Tables S1−S4). At all treatment times (24 and 72 h),
100% survival of Galleria was observed. Reduction in bacterial
numbers was concentration-dependent for the 24 h treatment
group with 2% w/v NapFFKK-OH having the greatest
antimicrobial activity against all pathogens; however, no results
were statistically significant at the 24 h time point. The findings
are biologically and clinically interesting, given that greater than
3 log10 CFU/mL bacterial reduction was obtained against S.
aureus for 2% w/v NapFFKK-OH.35,36 At least a 2 log10 CFU/
mL reduction in bacterial numbers was observed for 2% w/v
NapFFKK-OH against all pathogens after 72 h, the greatest and
also most significant (p < 0.001) being 4.4 log10 CFU/mL
against S. aureus. The authors recognize that again there is a lack
of statistical significance against other pathogens at both 24 and
72 h time points. However, a reduction in bacterial load is
demonstrated and the G. mellonellamodel serves as a useful tool
in vivo.
The inoculating doses and techniques used in these
investigations are similar to those conducted by other research
groups. Gibreel and Upton,22 for example, employed a higher
dose of S. aureus (2.5 × 106 CFU/mL); however, the methods
used reflect our own studies and determine peptide toxicity and
larval viability over 120 h. Interestingly, they also determined in
vivo stability and activity as concentration-dependent and
determined that peptide degradation occurred at concentrations
less than 50 mg/kg. Leuko and Raivio37 crushed G. mellonella to
determine bacterial counts, as opposed to hemolymph
extraction employed in this work. Crushing was avoided in
this work to prevent contamination of the test pathogen with
commensal gut bacteria.38 Prophylaxis with a standard antibiotic
to reduce gut bacteria was not performed as only one
formulation was investigated. In addition, prophylaxis may
trigger upregulation of first-line inherent antimicrobial peptides;
these may positively enhance the apparent antimicrobial activity
of the test peptide.17
The antimicrobial mechanism of action of NapFFKK-OH is
likely to follow that of other peptides whereby hydrophobicity
and cationic charge enable the formation of ion channels in
bacterial membranes and/or a surfactant-like action. Recent
research has also shown a link between antimicrobial activity and
molecular folding, structural conformation and assembly
state.39−41 Self-assembly has been increasingly linked to
improved antimicrobial activity within peptides and proteins.
β-amyloid, implicated as the main component of plaques linked
to Alzheimer’s and to which diphenyalanine (FF) forms a
fundamental component of self-assembly, demonstrates sig-
nificant antibacterial activity.42,43 β-amyloid forms transmem-
branous pores in bacterial membranes, leading to membrane
depolarization and cell death. Although this is a feasible
mechanism for NapFFKK-OH, especially given the presence
of the key β-amyloid motif FF, it is more likely that our hydrogel
acts similarly to Schneider’s β-hairpin peptide hydrogels (MAX,
MARG, and PEP6R).44−46 The combination of local cationic
charge on the NpxFFKK-OH hydrogel surface and the porous
network of cross-linked nanofibers allows increased interaction
with anionic constituents of bacterial membranes, leading to
membrane disruption and cell death.
■ CONCLUSIONS
In this study, we have tested the in vivo antimicrobial properties
of an ultrashort antimicrobial peptide hydrogel NapFFKK-OH
using a unique G. mellonella infection model and a range of
healthcare-associated Gram-positive and Gram-negative patho-
gens. G. mellonella is gaining increasing interest as an alternative
model for mammalian in vivo testing and is particularly relevant
for the testing of novel antimicrobial platforms, such as our
NapFFKK-OH hydrogel. There is increasing need for the
validation of techniques employed when using these models to
confirm the reliability of the data produced. Previous
investigations have indicated that there may be variations
depending on the batch and/or the supplier. In addition, there is
not any reference population yet (size, gene function, sequence,
or phenotype); thus, standardization is required.
■ METHODS
Peptide Synthesis. Fmoc- and Boc-protected amino acids,
N,N,N′,N′-tetramethyl-O-(1H-benzotriazol-1-yl)uronium hex-
afluorophosphate (HBTU), N,N-diisopropylethylamine
(DIEA), 1-hydroxybenzotriazole (HOBt), and Wang resin
(mesh size 100−200, 0.65 mmol/g), were obtained from
Novabiochem, Merck KGaA (Darmstadt, Germany). The
NapFFKK-OH peptide (Figure S1) was synthesized following
standard Fmoc solid phase synthesis protocols, as previously
outlined.10 Synthesis was performed manually on lysine-
conjugated Wang resin with elongation achieved using 4
molar equivalents (meq) of HBTU, 8 meq of DIEA, 4 meq of
HOBt, and 4meq of Fmoc-protected amino acid or naphthalene
acetic acid. Peptides were cleaved from the resin using 95%
trifluoro acetic acid (TFA), 2.5% triisopropylsilane, and 2.5%
thioanisole.
Peptide identity and purity were determined by electrospray
ionization mass spectroscopy, 1H NMR (Varian Unity Inova
400 spectrometer) using DMSO-d6, and reverse-phase HPLC
(Agilent 1260 Infinity system fitted with a Gemini C18 250 mm
× 4.6 mm column; 100 − 80% gradient over 20 min of 0.05%
TFA−water/acetonitrile and a flow rate of 1 mL/min).
Hydrogels were formulated using 0.5 M HCl, 1 M NaOH, and
sterile deionized water as previously demonstrated by our
group.28
NapFFKK-OH In Vivo Toxicity. A method similar to that
used by Gibreel and Upton was used to assess peptide hydrogel
toxicity.22 G. mellonella larvae (Livefoods Direct Ltd., Yorkshire,
U.K.) were stored at 15 °C until required for use. They were not
fed as it is recommended to starve the larvae for at least 24 h
prior to use.16 Five larvae were inoculated with 20 μL of each
peptide hydrogel (0.5−2% w/v) injected into the hemolymph
via the bottom left proleg using 29G insulin syringes (0.3 mL)
with needles (Figure 4). Percentage survival was monitored over
120 h by recording live/dead counts at 24, 48, 72, and 120 h.
Toxicity was determined on the basis of percentage survival,
where 100% survival during the experiment time represented
minimal toxicity for that peptide and concentration (0.5−2% w/
v). Toxicity was measured at two different temperatures 30 and
37 °C to see whether this would have an impact on G. mellonella
survival. Controls were provided in the form of untreated larvae,
and these were injected separately with PBS and the comprising
elements of the peptide hydrogel (deionized water, 1 M NaOH,
and 0.5 M HCl) in the relevant volumes for each hydrogel
concentration (Figure S2).18,28
Verifying Maximum Nonlethal Dose of Bacteria.
Methods similar to those of Hornsey and Wareham were used
to conduct validation and antimicrobial studies.12 Overnight
bacterial cultures of the test bacteria (S. epidermidis ATCC
35984, S. aureus ATCC 6538, E. coli NCTC 11303, and P.
aeruginosa PAO1) were grown inMueller-Hinton broth (MHB)
at 37 °C and adjusted using PBS to 1× 108 CFU/mL and serially
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diluted. As per the toxicity study, sets of five larvae for each
dilution (1 × 108−1 × 102) were inoculated the bottom left
proleg with 20 μL of bacteria. Live/dead counts were recorded at
24, 48, 72, and 120 h and are presented in Tables S1−S4. We
defined the maximum nonlethal dose as the one at which there
was 80% or greater larvae survival.18 Following determination, a
suitable inoculum concentration was selected (the one at which
there was >80% survival after 120 h) and prepared using PBS
from an overnight culture (grown, as detailed, in MHB at 37 °C
in a gyrorotary incubator). Larvae were inoculated with the
maximum nonlethal dose of bacteria via the bottom left proleg.
NapFFKK-OH was selected as the model antimicrobial
hydrogel due to its broad-spectrum antibiofilm activity
demonstrated previously by our group against in vitro biofilm
models.10
Infection Models. Triplicate sets of five Galleria larvae were
infected with 20 μL of the maximum nonlethal bacterial dose
with antimicrobial treatment in the form of NapFFKK-OH
administered via injection into the bottom right proleg 2 h after
inoculation with the test microorganism, as utilized by Aperis
and colleagues.47 An equivalent volume of peptide hydrogel to
bacterial inoculum was used (20 μL), and 0.5−2% w/v
concentrations of peptide were used. The larvae were incubated
at 37 °C for 24 or 72 h after which hemolymph was extracted. In
each case, controls were provided in the form of larvae
inoculated with bacteria only (maximum nonlethal dose) and
larvae injected with PBS only. These represented untreated
(negative control) and uninfected control larvae, respectively.
Hemolymph Extraction and Bacterial Enumeration.
Following the appropriate incubation time (24 or 72 h), larvae
were placed in a falcon tube on ice for 10 min to aid handling.
Anesthetized larvae were placed in a sterile Petri dish, and a
sterile scalpel was used to make an incision between the bottom
two prolegs where inoculation had occurred. Hemolymph was
collected from the five larvae per treatment group in a sterile 1.5
mL microcentrifuge tube. Hemolymph was serially diluted in
PBS (10−1 − 10−6). Miles and Misra bacterial viability counts
were performed using MHA of dilutions 10−3 − 10−6 and
incubated overnight at 37 °C. Hemolymph was diluted and
plated within 10 min to prevent it turning brown and
coagulating. The Miles and Misra plates were counted 24 h
following incubation, and log10 CFU/mL bacterial reduction
was determined.47
Statistical Analysis. Results were analyzed using GraphPad
Prism, 6.0. Reduction in log10 CFU/mL bacterial numbers was
analyzed following inoculation, and treatment with NapFFKK-
OH included employment of one-way analysis of variance and
Tukey’s posthoc test to identify individual differences. This
enabled comparisons to be made between changes in bacterial
counts in the hemolymph of treated Galleria larvae compared to
those of the positive untreated (maximum nonlethal dose)
controls.
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